News and Trends 2 Sep 2022Beyond Biotech podcast 12: Gate Neurosciences, Oncolyze, 3Brain This week’s podcast guests are Mike McCully, CEO of Gate Neurosciences; Steven Evans, CEO and co-founder of Oncolyze; and Philipp Markolin, scientific marketing specialist at 3Brain. We also have our weekly chat with global commercial real estate services company JLL, and this week it’s a chat with Amber Schiada, head of life sciences research in […] September 2, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Manus Bio receives additional funding to fight malaria with biotech U.S. biomanufacturer Manus Bio has received a fourth award from the Bill & Melinda Gates Foundation to develop a scalable production route for the potential antimalarial drug, artemisinin. The $2 million award will enable Manus Bio to begin scaling up the biological process it has developed towards the chemical intermediate, dihydroartemisinic acid. Economical and scalable […] September 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 New discovery could lead to drug development for brain cancer According to researchers, a study at Tel Aviv University in Israel effectively eradicated glioblastoma, a highly lethal type of brain cancer. The researchers achieved the outcome using a method they developed based on their discovery of two critical mechanisms in the brain that support tumor growth and survival: one protects cancer cells from the immune […] September 1, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Proxidrugs: a new tool to fight pathogens? Scientists at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Germany are working with partners to develop a new drug class. Proxidrugs (or proximity-inducing drugs) utilize cells’ waste disposal system as potential new treatments for cancer, infections and Alzheimer’s disease. Aimo Kannt, head of drug discovery and preclinical research at Fraunhofer ITMP in […] September 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Study of injection to treat schizophrenia to begin after $3M payment received A phase 3 clinical trial for an injection to treat patients with schizophrenia has been initiated after a $3 million payment was received by MedinCell. Teva Pharmaceuticals made the decision to start the trial for mdc-TJK this week (August 29). Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia can produce a […] September 1, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Brainomix awarded tender to deploy AI stroke imaging across whole of Hungary Artificial intelligence (AI) stroke imaging will be deployed across centers in Hungary after Brainomix was awarded a national tender. The company was granted the tender for all stroke centers in the country as part of the National Institute for Health Development initiative to improve stroke care. Following a competitive process, the five-year program that was […] September 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Provention Bio looks to advance diabetes drug through $125M loan U.S. biopharma company Provention Bio, Inc. has secured a term loan facility of up to $125 million with Hercules Capital, Inc. ahead of the company’s potential launch of teplizumab. The BLA for teplizumab, Provention Bio’s lead investigational drug candidate, for the delay of progression to stage 3 clinical type 1 diabetes in at-risk individuals has […] September 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 License agreement signed allowing drug to treat mycosis fungoides to expand in Asia, Australia and the Middle East A license agreement has been signed between Helsinn Group and Juniper Biologics further widening the scope for distribution of T-cell lymphoma treatment, LEGADA. The license signifies a supply agreement to register, distribute, promote, market and sell the drug in Australia, Asia and the Middle East as a topical treatment of the mycosis fungoides-type cutaneous T-cell […] September 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Sanofi’s first treatment in the U.S. approved for adults and children with ASMD A rare, inherited disease that affects the body’s ability to metabolize fat, cholesterol and lipids within cells can now be treated by Xenpozyme, a drug approved by the U.S. Food and Drug Administration (FDA). Adults and children with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) can now take healthcare company Sanofi’s Xenpozyme […] September 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Labiotech adds conference and event listings In the past few months, Labiotech.eu has boosted its coverage range to go global, added a podcast, expanded to three weekly newsletters, introduced special monthly newsletters, and now we’ve added another string to our bow – conference and event listings. The page is designed so visitors can easily jump between months and events. Listings have […] September 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 1 Sep 2022 The evolution of diabetes management Diabetes management has progressed leaps and bounds in the last 100 years. Francine Kaufman, Chief Medical Officer of Senseonics, outlines how far the field has progressed and what is on the horizon for diabetes patients. This year marks 100 years since insulin was first available to treat diabetes – an incredible milestone. One of the […] September 1, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Ensysce Biosciences and Quotient Sciences to develop opioid to prevent abuse and overdose Ensysce Biosciences, Inc., a clinical-stage biotech company, and Quotient Sciences, a drug development and manufacturing accelerator, are partnering to support the development and clinical testing of PF614-MPAR. PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. Quotient Sciences is currently using […] September 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email